

# Zvi G Fridlender

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5325722/publications.pdf>

Version: 2024-02-01

60  
papers

7,786  
citations

186265

28  
h-index

155660

55  
g-index

61  
all docs

61  
docs citations

61  
times ranked

9985  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Bilateral Interplay between Cancer Immunotherapies and Neutrophilsâ€™ Phenotypes and Sub-Populations. <i>Cells</i> , 2022, 11, 783.	4.1	6
2	Editorial: Neutrophils in Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 862257.	4.8	0
3	Residual symptoms, lung function, and imaging findings in patients recovering from SARS-CoV-2 infection. <i>Internal and Emergency Medicine</i> , 2022, 17, 1491-1501.	2.0	8
4	Accelerated low-density neutrophil transition in sickle cell anaemia may contribute to disease pathophysiology. <i>British Journal of Haematology</i> , 2022, 197, 232-235.	2.5	5
5	Universal lung epithelium DNA methylation markers for detection of lung damage in liquid biopsies. <i>European Respiratory Journal</i> , 2022, 60, 2103056.	6.7	10
6	Neutrophil phenotypes and functions in cancer: A consensus statement. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	119
7	Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression. <i>Cancers</i> , 2021, 13, 726.	3.7	20
8	Therapeutic Success of Tiotropium/Olodaterol, Measured Using the Clinical COPD Questionnaire (CCQ), in Routine Clinical Practice: A Multinational Non-Interventional Study. <i>International Journal of COPD</i> , 2021, Volume 16, 615-628.	2.3	4
9	Tumor-Associated Neutrophils Drive B-cell Recruitment and Their Differentiation to Plasma Cells. <i>Cancer Immunology Research</i> , 2021, 9, 811-824.	3.4	17
10	Tumor-Derived Factors Differentially Affect the Recruitment and Plasticity of Neutrophils. <i>Cancers</i> , 2021, 13, 5082.	3.7	8
11	The dual role of neutrophils in cancer. <i>Seminars in Immunology</i> , 2021, 57, 101582.	5.6	26
12	Prophylactic use of tranexamic acid for prevention of bleeding during transbronchial lung biopsies - A randomized, double-blind, placebo-controlled trial. <i>Respiratory Medicine</i> , 2020, 173, 106162.	2.9	3
13	NETosis in cancer: a critical analysis of the impact of cancer on neutrophil extracellular trap (NET) release in lung cancer patients vs. mice. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 199-213.	4.2	39
14	Circulating neutrophil subsets in advanced lung cancer patients exhibit unique immune signature and relate to prognosis. <i>FASEB Journal</i> , 2020, 34, 4204-4218.	0.5	70
15	The Effect of a Multidisciplinary Integrated Approach on Outcomes in Chronic Obstructive Pulmonary Disease. <i>Israel Medical Association Journal</i> , 2020, 22, 761-764.	0.1	0
16	Interactions among myeloid regulatory cells in cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 645-660.	4.2	42
17	<p>Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2343-2354.	2.3	16
18	Increased Regeneration Following Stress-Induced Lung Injury in Bleomycin-Treated Chimeric Mice with CD44 Knockout Mesenchymal Cells. <i>Cells</i> , 2019, 8, 1211.	4.1	7

#	ARTICLE	IF	CITATIONS
19	VICKZ1 enhances tumor progression and metastasis in lung adenocarcinomas in mice. <i>Oncogene</i> , 2019, 38, 4169-4181.	5.9	24
20	Neutrophil Diversity in Health and Disease. <i>Trends in Immunology</i> , 2019, 40, 565-583.	6.8	308
21	Tumour-associated neutrophils in patients with cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 601-620.	27.6	558
22	Inhaled therapies in patients with moderate COPD in clinical practice: current thinking. <i>International Journal of COPD</i> , 2018, Volume 13, 45-56.	2.3	13
23	TRPM2 Mediates Neutrophil Killing of Disseminated Tumor Cells. <i>Cancer Research</i> , 2018, 78, 2680-2690.	0.9	120
24	Myeloid Regulatory Cells: New and Exciting Players in the Immunology of Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 703-704.	5.6	2
25	Cancer-related circulating and tumor-associated neutrophils "subtypes, sources and function. <i>FEBS Journal</i> , 2018, 285, 4316-4342.	4.7	156
26	Microenvironmental Cues Determine Tumor Cell Susceptibility to Neutrophil Cytotoxicity. <i>Cancer Research</i> , 2018, 78, 5050-5059.	0.9	29
27	Combined Administration of Recombinant TGF- $\beta$ 1 and DMSO Decreases the in Vitro Inflammatory Properties of Neutrophils from Sickle Cell Anemia Individuals. <i>Blood</i> , 2018, 132, 2366-2366.	1.4	0
28	The diversity of circulating neutrophils in cancer. <i>Immunobiology</i> , 2017, 222, 82-88.	1.9	109
29	Neutrophils as active regulators of the immune system in the tumor microenvironment. <i>Journal of Leukocyte Biology</i> , 2017, 102, 343-349.	3.3	153
30	Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?. <i>Clinical and Translational Immunology</i> , 2017, 6, e134.	3.8	32
31	Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNF $\alpha$ and NO-dependent mechanism, promoting a tumor-supportive environment. <i>Oncolmmunology</i> , 2017, 6, e1356965.	4.6	103
32	The association between osteopontin gene polymorphisms, osteopontin expression and sarcoidosis. <i>PLoS ONE</i> , 2017, 12, e0171945.	2.5	8
33	Tumor-associated neutrophils display a distinct N1 profile following TGF $\beta$ 2 modulation: A transcriptomics analysis of pro- vs. antitumor TANs. <i>Oncolmmunology</i> , 2016, 5, e1232221.	4.6	173
34	Isolation and Characterization of Neutrophils with Anti-Tumor Properties. <i>Journal of Visualized Experiments</i> , 2015, , e52933.	0.3	25
35	Phenotypic Diversity and Plasticity in Circulating Neutrophil Subpopulations in Cancer. <i>Cell Reports</i> , 2015, 10, 562-573.	6.4	640
36	Plasticity beyond Cancer Cells and the "Immunosuppressive Switch". <i>Cancer Research</i> , 2015, 75, 4441-4445.	0.9	70

#	ARTICLE	IF	CITATIONS
37	Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response. <i>Oncolmmunology</i> , 2015, 4, e998469.	4.6	41
38	Promoting metastasis: neutrophils and T cells join forces. <i>Cell Research</i> , 2015, 25, 765-766.	12.0	25
39	The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment. <i>Cancer Microenvironment</i> , 2015, 8, 125-158.	3.1	315
40	Neutrophils recruit regulatory T cells into tumors via secretion of CCL17: A new mechanism of impaired antitumor immunity. <i>International Journal of Cancer</i> , 2014, 135, 1178-1186.	5.1	184
41	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of lung cancer management. <i>Lung Cancer Management</i> , 2014, 3, 13-15.	1.5	0
42	Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1745-1756.	4.2	281
43	Modifying tumor-associated macrophages. <i>Oncolmmunology</i> , 2013, 2, e26620.	4.6	17
44	The Role of Tumor Associated Neutrophils in Cancer. , 2013, , 457-478.		0
45	Randomized Controlled Crossover Trial of a New Oscillatory Device as Add-On Therapy for COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012, 9, 603-610.	1.6	2
46	A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation. <i>Cancer Biology and Therapy</i> , 2012, 13, 745-755.	3.4	27
47	Treating Tumors With a Vaccinia Virus Expressing IFN $\gamma$ Illustrates the Complex Relationships Between Oncolytic Ability and Immunogenicity. <i>Molecular Therapy</i> , 2012, 20, 736-748.	8.2	38
48	Tumor-associated neutrophils: friend or foe?. <i>Carcinogenesis</i> , 2012, 33, 949-955.	2.8	550
49	Transcriptomic Analysis Comparing Tumor-Associated Neutrophils with Granulocytic Myeloid-Derived Suppressor Cells and Normal Neutrophils. <i>PLoS ONE</i> , 2012, 7, e31524.	2.5	247
50	Characterization of surgical models of postoperative tumor recurrence for preclinical adjuvant therapy assessment. <i>American Journal of Translational Research (discontinued)</i> , 2012, 4, 206-18.	0.0	5
51	Monocyte Chemoattractant Protein-1 Blockade Inhibits Lung Cancer Tumor Growth by Altering Macrophage Phenotype and Activating CD8 <sup>+</sup> Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 44, 230-237.	2.9	122
52	Chemotherapy Delivered After Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-mediated Mechanisms. <i>Molecular Therapy</i> , 2010, 18, 1947-1959.	8.2	120
53	CCL2 Blockade Augments Cancer Immunotherapy. <i>Cancer Research</i> , 2010, 70, 109-118.	0.9	159
54	Association between CD14 gene polymorphisms and disease phenotype in sarcoidosis. <i>Respiratory Medicine</i> , 2010, 104, 1336-1343.	2.9	7

#	ARTICLE	IF	CITATIONS
55	Polarization of Tumor-Associated Neutrophil Phenotype by TGF- $\beta$ 2: $\alpha$ 1 versus $\alpha$ 2-TAN. <i>Cancer Cell</i> , 2009, 16, 183-194.	16.8	2,522
56	B-cell Depletion Using an Anti-CD20 Antibody Augments Antitumor Immune Responses and Immunotherapy in Nonhematopoietic Murine Tumor Models. <i>Journal of Immunotherapy</i> , 2008, 31, 446-457.	2.4	69
57	Systemic Blockade of Transforming Growth Factor- $\beta$ 2 Signaling Augments the Efficacy of Immunogene Therapy. <i>Cancer Research</i> , 2008, 68, 10247-10256.	0.9	85
58	Association Between Cytomegalovirus Infection and Venous Thromboembolism. <i>American Journal of the Medical Sciences</i> , 2007, 334, 111-114.	1.1	21
59	Obstructing Tracheal Pulmonary Langerhans Cell Histiocytosis. <i>Chest</i> , 2005, 128, 1057-1058.	0.8	11
60	Mefloquine-Induced Acute Hepatitis. <i>Pharmacotherapy</i> , 2000, 20, 1517-1519.	2.6	15